Next Article in Journal
Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases
Previous Article in Journal
Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome
Article

Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor

1
Department of Craniofacial Biology, School of Dental Medicine, University of Colorado|Anschutz Medical Campus, Aurora, CO 80045, USA
2
Department of Ophthalmology, University of Colorado School of Medicine|Anschutz Medical Campus, Aurora, CO 80045, USA
3
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado|Anschutz Medical Campus, Aurora, CO 80045, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Mario Cappiello
Biomolecules 2021, 11(8), 1150; https://doi.org/10.3390/biom11081150
Received: 22 June 2021 / Revised: 28 July 2021 / Accepted: 30 July 2021 / Published: 4 August 2021
(This article belongs to the Special Issue Aldose Reductase: Functions, Inhibitors and Molecular Mechanisms)
Cataracts are a leading cause of blindness worldwide. Surgical removal of cataracts is a safe and effective procedure to restore vision. However, a large number of patients later develop vision loss due to regrowth of lens cells and subsequent degradation of the visual axis leading to visual disability. This postsurgical complication, known as posterior capsular opacification (PCO), occurs in up to 30% of cataract patients and has no clinically proven pharmacological means of prevention. Despite the availability of many compounds capable of preventing early steps in PCO development, there is currently no effective means to deliver such therapies into the eye for a suitable duration. To model a solution to this unmet medical need, we fabricated acrylic substrates as intraocular lens (IOL) mimics scaled to place into the capsular bag of the mouse lens following a mock-cataract surgery. Substrates were coated with a hydrophilic crosslinked acrylate nanogel designed to elute Sorbinil, an aldose reductase inhibitor previously shown to suppress PCO. Insertion of the Sorbinil-eluting device into the lens capsule at the time of cataract surgery resulted in substantial prevention of cellular changes associated with PCO development. This model demonstrates that a cataract inhibitor can be delivered into the postsurgical lens capsule at therapeutic levels. View Full-Text
Keywords: posterior capsule opacification; cataract; nanogel; drug delivery; aldose reductase; Sorbinil posterior capsule opacification; cataract; nanogel; drug delivery; aldose reductase; Sorbinil
Show Figures

Figure 1

MDPI and ACS Style

Gautam, D.; Pedler, M.G.; Nair, D.P.; Petrash, J.M. Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor. Biomolecules 2021, 11, 1150. https://doi.org/10.3390/biom11081150

AMA Style

Gautam D, Pedler MG, Nair DP, Petrash JM. Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor. Biomolecules. 2021; 11(8):1150. https://doi.org/10.3390/biom11081150

Chicago/Turabian Style

Gautam, Dixa, Michelle G. Pedler, Devatha P. Nair, and Jonathan M. Petrash 2021. "Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor" Biomolecules 11, no. 8: 1150. https://doi.org/10.3390/biom11081150

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop